Kleanthis Gabriel Xanthopoulos
Known title: DirectorCIK: 0002115875
Associated companies
Transaction History
| CNTB | ▲ Buy | Grant | 5,000 | $0 | 9/30/2026 | View on chart |
| CNTB | ▲ Buy | Grant | 3,738 | $0 | 6/30/2026 | View on chart |
| CNTB | ▲ Buy | Grant | 2,816 | $0 | 3/31/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
CNTB Misses Asthma Trial Goal as Oppenheimer Lowers Target
Connect Biopharma reported that its latest asthma trial did not meet the primary endpoint. The result may affect the progression of the drug program. Oppenheimer kept an Outperform rating but reduced its price target to $5, below the consensus $6.50. The stock is currently trading near its recent support level.
CNTB Misses Asthma Trial Goal as Oppenheimer Lowers Target. Connect Biopharma reported that its latest asthma trial did not meet the primary endpoint. The result may affect the progression of the drug program. Oppenheimer kept an Outperform rating but reduced its price target to $5, below the consensus $6.50. The stock is currently trading near its recent support level.